Key clinical point: The entheseal fibrocartilage (EF) thickness assessed during power Doppler ultrasound evaluation was significantly different among patients with psoriatic arthritis (PsA) and control individuals and can be explored as an imaging biomarker for PsA.

Major finding: The median EF thickness was significantly greater in patients with PsA and athletes vs control individuals (0.035 and 0.036 vs 0.030 cm, respectively; P  =  .05 and P  =  .008, respectively), with the intra- and inter-reader reliability of the evaluation of EF thickness being excellent (intraclass correlation coefficient [ICC] 0.91) and good (ICC 0.80; both P < .001), respectively.

Study details: This cross-sectional study included patients with PsA (n = 30), athletes (n = 40), and control individuals (n = 20) who underwent power Doppler ultrasound evaluation during bilateral Achilles tendon insertions.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Perrotta FM et al. Ultrasonographic evaluation of entheseal fibrocartilage in patients with psoriatic arthritis, athletes and healthy controls: A comparison study. Diagnostics (Basel). 2023;13(8):1446 (Apr 17). Doi: 10.3390/diagnostics13081446

Key clinical point: The entheseal fibrocartilage (EF) thickness assessed during power Doppler ultrasound evaluation was significantly different among patients with psoriatic arthritis (PsA) and control individuals and can be explored as an imaging biomarker for PsA.

Major finding: The median EF thickness was significantly greater in patients with PsA and athletes vs control individuals (0.035 and 0.036 vs 0.030 cm, respectively; P  =  .05 and P  =  .008, respectively), with the intra- and inter-reader reliability of the evaluation of EF thickness being excellent (intraclass correlation coefficient [ICC] 0.91) and good (ICC 0.80; both P < .001), respectively.

Study details: This cross-sectional study included patients with PsA (n = 30), athletes (n = 40), and control individuals (n = 20) who underwent power Doppler ultrasound evaluation during bilateral Achilles tendon insertions.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Perrotta FM et al. Ultrasonographic evaluation of entheseal fibrocartilage in patients with psoriatic arthritis, athletes and healthy controls: A comparison study. Diagnostics (Basel). 2023;13(8):1446 (Apr 17). Doi: 10.3390/diagnostics13081446

Key clinical point: The entheseal fibrocartilage (EF) thickness assessed during power Doppler ultrasound evaluation was significantly different among patients with psoriatic arthritis (PsA) and control individuals and can be explored as an imaging biomarker for PsA.

Major finding: The median EF thickness was significantly greater in patients with PsA and athletes vs control individuals (0.035 and 0.036 vs 0.030 cm, respectively; P  =  .05 and P  =  .008, respectively), with the intra- and inter-reader reliability of the evaluation of EF thickness being excellent (intraclass correlation coefficient [ICC] 0.91) and good (ICC 0.80; both P < .001), respectively.

Study details: This cross-sectional study included patients with PsA (n = 30), athletes (n = 40), and control individuals (n = 20) who underwent power Doppler ultrasound evaluation during bilateral Achilles tendon insertions.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Perrotta FM et al. Ultrasonographic evaluation of entheseal fibrocartilage in patients with psoriatic arthritis, athletes and healthy controls: A comparison study. Diagnostics (Basel). 2023;13(8):1446 (Apr 17). Doi: 10.3390/diagnostics13081446

Key clinical point: Compared with placebo, 15 mg upadacitinib led to a greater improvement in axial symptoms with a consistent safety profile in patients with psoriatic arthritis (PsA).

Major finding: The improvement in overall Bath Ankylosing Spondylitis Disease Activity Index score at week 24 was significantly higher with 15 mg upadacitinib vs placebo in both SELECT-PsA 1 (−3.12 vs −1.70; P < .0001) and SELECT PsA 2 (−2.06 vs −0.21; P < .0001) trials. Treatment-emergent adverse events were generally similar among the sub-groups.

Study details: This post hoc analysis included patients with active PsA (n = 1,281 and n = 423, respectively) from the SELECT-PsA 1 and SELECT-PsA 2 trials who were randomly assigned to receive either 15 mg upadacitinib, placebo, or adalimumab and were categorized as those with or without axial involvement.

Disclosures: This study was funded by AbbVie. Five authors declared being employees or stockholders of AbbVie, and some authors reported ties with various sources, including AbbVie.

Source: Baraliakos X et al. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: Results from two phase 3 studies. Arthritis Res Ther. 2023;25:56 (Apr 10). Doi: 10.1186/s13075-023-03027-5

Key clinical point: Compared with placebo, 15 mg upadacitinib led to a greater improvement in axial symptoms with a consistent safety profile in patients with psoriatic arthritis (PsA).

Major finding: The improvement in overall Bath Ankylosing Spondylitis Disease Activity Index score at week 24 was significantly higher with 15 mg upadacitinib vs placebo in both SELECT-PsA 1 (−3.12 vs −1.70; P < .0001) and SELECT PsA 2 (−2.06 vs −0.21; P < .0001) trials. Treatment-emergent adverse events were generally similar among the sub-groups.

Study details: This post hoc analysis included patients with active PsA (n = 1,281 and n = 423, respectively) from the SELECT-PsA 1 and SELECT-PsA 2 trials who were randomly assigned to receive either 15 mg upadacitinib, placebo, or adalimumab and were categorized as those with or without axial involvement.

Disclosures: This study was funded by AbbVie. Five authors declared being employees or stockholders of AbbVie, and some authors reported ties with various sources, including AbbVie.

Source: Baraliakos X et al. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: Results from two phase 3 studies. Arthritis Res Ther. 2023;25:56 (Apr 10). Doi: 10.1186/s13075-023-03027-5

Key clinical point: Compared with placebo, 15 mg upadacitinib led to a greater improvement in axial symptoms with a consistent safety profile in patients with psoriatic arthritis (PsA).

Major finding: The improvement in overall Bath Ankylosing Spondylitis Disease Activity Index score at week 24 was significantly higher with 15 mg upadacitinib vs placebo in both SELECT-PsA 1 (−3.12 vs −1.70; P < .0001) and SELECT PsA 2 (−2.06 vs −0.21; P < .0001) trials. Treatment-emergent adverse events were generally similar among the sub-groups.

Study details: This post hoc analysis included patients with active PsA (n = 1,281 and n = 423, respectively) from the SELECT-PsA 1 and SELECT-PsA 2 trials who were randomly assigned to receive either 15 mg upadacitinib, placebo, or adalimumab and were categorized as those with or without axial involvement.

Disclosures: This study was funded by AbbVie. Five authors declared being employees or stockholders of AbbVie, and some authors reported ties with various sources, including AbbVie.

Source: Baraliakos X et al. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: Results from two phase 3 studies. Arthritis Res Ther. 2023;25:56 (Apr 10). Doi: 10.1186/s13075-023-03027-5

Key clinical point: Sonographic enthesitis showed strong association with sonographic synovitis and tenosynovitis in patients with psoriatic arthritis (PsA), suggesting the clinical significance of sonographic enthesitis as a potential marker for inflammation in other musculoskeletal domains.

Major finding: Sonographic enthesitis was significantly associated with sonographic synovitis (β 0.19; P  =  .004) and sonographic tenosynovitis (β 0.1; P  =  .003) and showed strong correlation with patient-reported outcomes, such as Health Assessment Questionnaire (P  =  .003), morning stiffness (P  =  .002), and others.

Study details: This study prospectively recruited 158 patients with PsA who underwent sonographic assessment of 52 joints, 40 tendons, and 14 entheses points along with clinical evaluation.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Balulu G et al. The association between sonographic enthesitis with sonographic synovitis and tenosynovitis in psoriatic arthritis patients. Rheumatology (Oxford). 2023 (May 11). Doi: 10.1093/rheumatology/kead202

Key clinical point: Sonographic enthesitis showed strong association with sonographic synovitis and tenosynovitis in patients with psoriatic arthritis (PsA), suggesting the clinical significance of sonographic enthesitis as a potential marker for inflammation in other musculoskeletal domains.

Major finding: Sonographic enthesitis was significantly associated with sonographic synovitis (β 0.19; P  =  .004) and sonographic tenosynovitis (β 0.1; P  =  .003) and showed strong correlation with patient-reported outcomes, such as Health Assessment Questionnaire (P  =  .003), morning stiffness (P  =  .002), and others.

Study details: This study prospectively recruited 158 patients with PsA who underwent sonographic assessment of 52 joints, 40 tendons, and 14 entheses points along with clinical evaluation.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Balulu G et al. The association between sonographic enthesitis with sonographic synovitis and tenosynovitis in psoriatic arthritis patients. Rheumatology (Oxford). 2023 (May 11). Doi: 10.1093/rheumatology/kead202

Key clinical point: Sonographic enthesitis showed strong association with sonographic synovitis and tenosynovitis in patients with psoriatic arthritis (PsA), suggesting the clinical significance of sonographic enthesitis as a potential marker for inflammation in other musculoskeletal domains.

Major finding: Sonographic enthesitis was significantly associated with sonographic synovitis (β 0.19; P  =  .004) and sonographic tenosynovitis (β 0.1; P  =  .003) and showed strong correlation with patient-reported outcomes, such as Health Assessment Questionnaire (P  =  .003), morning stiffness (P  =  .002), and others.

Study details: This study prospectively recruited 158 patients with PsA who underwent sonographic assessment of 52 joints, 40 tendons, and 14 entheses points along with clinical evaluation.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Balulu G et al. The association between sonographic enthesitis with sonographic synovitis and tenosynovitis in psoriatic arthritis patients. Rheumatology (Oxford). 2023 (May 11). Doi: 10.1093/rheumatology/kead202

Key clinical point: Patients with psoriatic arthritis (PsA) achieved enthesitis resolution over 52 weeks with secukinumab treatment, which was comparable to that with adalimumab treatment.

Major finding: At week 52, secukinumab vs adalimumab led to a similar proportion of patients achieving enthesitis resolution (53.2% vs 51.4%) along with site-specific resolution of lateral epicondyle enthesitis (84.6% vs 87.1%) and showing relapse after first resolution (21.0% vs 15.6%), as assessed by the Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC). Moreover, secukinumab vs adalimumab had a comparable response time to SPARCC enthesitis resolution (113 vs 88 days).

Study details: This post hoc analysis of the EXCEED study included 853 patients with PsA who received either secukinumab (300 mg) or adalimumab (40 mg) over 52 weeks.

Disclosures: This study was supported by Novartis Pharmaceuticals Corporation, USA. C Gaillez and B Parikh declared being current or former employees of Novartis Pharma or Novartis Pharmaceuticals Corporation, and several authors reported ties with various sources, including Novartis.

Source: Kaeley GS et al. Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: A post hoc analysis of the EXCEED study. Rheumatology (Oxford). 2023 (Apr 25). Doi: 10.1093/rheumatology/kead181

Key clinical point: Patients with psoriatic arthritis (PsA) achieved enthesitis resolution over 52 weeks with secukinumab treatment, which was comparable to that with adalimumab treatment.

Major finding: At week 52, secukinumab vs adalimumab led to a similar proportion of patients achieving enthesitis resolution (53.2% vs 51.4%) along with site-specific resolution of lateral epicondyle enthesitis (84.6% vs 87.1%) and showing relapse after first resolution (21.0% vs 15.6%), as assessed by the Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC). Moreover, secukinumab vs adalimumab had a comparable response time to SPARCC enthesitis resolution (113 vs 88 days).

Study details: This post hoc analysis of the EXCEED study included 853 patients with PsA who received either secukinumab (300 mg) or adalimumab (40 mg) over 52 weeks.

Disclosures: This study was supported by Novartis Pharmaceuticals Corporation, USA. C Gaillez and B Parikh declared being current or former employees of Novartis Pharma or Novartis Pharmaceuticals Corporation, and several authors reported ties with various sources, including Novartis.

Source: Kaeley GS et al. Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: A post hoc analysis of the EXCEED study. Rheumatology (Oxford). 2023 (Apr 25). Doi: 10.1093/rheumatology/kead181

Key clinical point: Patients with psoriatic arthritis (PsA) achieved enthesitis resolution over 52 weeks with secukinumab treatment, which was comparable to that with adalimumab treatment.

Major finding: At week 52, secukinumab vs adalimumab led to a similar proportion of patients achieving enthesitis resolution (53.2% vs 51.4%) along with site-specific resolution of lateral epicondyle enthesitis (84.6% vs 87.1%) and showing relapse after first resolution (21.0% vs 15.6%), as assessed by the Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC). Moreover, secukinumab vs adalimumab had a comparable response time to SPARCC enthesitis resolution (113 vs 88 days).

Study details: This post hoc analysis of the EXCEED study included 853 patients with PsA who received either secukinumab (300 mg) or adalimumab (40 mg) over 52 weeks.

Disclosures: This study was supported by Novartis Pharmaceuticals Corporation, USA. C Gaillez and B Parikh declared being current or former employees of Novartis Pharma or Novartis Pharmaceuticals Corporation, and several authors reported ties with various sources, including Novartis.

Source: Kaeley GS et al. Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: A post hoc analysis of the EXCEED study. Rheumatology (Oxford). 2023 (Apr 25). Doi: 10.1093/rheumatology/kead181

Key clinical point: The achievement of stringent treatment goals with secukinumab led to clinically meaningful benefits in physical function in patients with psoriatic arthritis (PsA), with secukinumab showing a protective effect on radiographic progression.

Major finding: Overall, over 2 years, a relatively small percentage of patients receiving secukinumab achieved sustained remission (REM) according to very low disease activity (LDA; 19%-24%) or Disease Activity index for PsA (DAPSA) REM (30%-36%), with those achieving DAPSA LDA+REM or DAPSA REM showing numerically greater improvement in physical function. A higher proportion of secukinumab-treated patients were non-structural progressors at 2 years irrespective of achieving sustained LDA/REM.

Study details: This was a retrospective analysis from the FUTURE 5 study including 996 patients with active PsA who were randomly assigned to receive secukinumab or placebo.

Disclosures: This study was funded by Novartis Pharma AG. Two authors declared being employees of or owning stocks/shares in Novartis, and several authors reported ties with various sources, including Novartis.

Source: Coates LC et al. Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: Results from the 2-year phase 3 FUTURE 5 study. RMD Open. 2023;9(2):e002939 (Apr 24). Doi: 10.1136/rmdopen-2022-002939

Key clinical point: The achievement of stringent treatment goals with secukinumab led to clinically meaningful benefits in physical function in patients with psoriatic arthritis (PsA), with secukinumab showing a protective effect on radiographic progression.

Major finding: Overall, over 2 years, a relatively small percentage of patients receiving secukinumab achieved sustained remission (REM) according to very low disease activity (LDA; 19%-24%) or Disease Activity index for PsA (DAPSA) REM (30%-36%), with those achieving DAPSA LDA+REM or DAPSA REM showing numerically greater improvement in physical function. A higher proportion of secukinumab-treated patients were non-structural progressors at 2 years irrespective of achieving sustained LDA/REM.

Study details: This was a retrospective analysis from the FUTURE 5 study including 996 patients with active PsA who were randomly assigned to receive secukinumab or placebo.

Disclosures: This study was funded by Novartis Pharma AG. Two authors declared being employees of or owning stocks/shares in Novartis, and several authors reported ties with various sources, including Novartis.

Source: Coates LC et al. Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: Results from the 2-year phase 3 FUTURE 5 study. RMD Open. 2023;9(2):e002939 (Apr 24). Doi: 10.1136/rmdopen-2022-002939

Key clinical point: The achievement of stringent treatment goals with secukinumab led to clinically meaningful benefits in physical function in patients with psoriatic arthritis (PsA), with secukinumab showing a protective effect on radiographic progression.

Major finding: Overall, over 2 years, a relatively small percentage of patients receiving secukinumab achieved sustained remission (REM) according to very low disease activity (LDA; 19%-24%) or Disease Activity index for PsA (DAPSA) REM (30%-36%), with those achieving DAPSA LDA+REM or DAPSA REM showing numerically greater improvement in physical function. A higher proportion of secukinumab-treated patients were non-structural progressors at 2 years irrespective of achieving sustained LDA/REM.

Study details: This was a retrospective analysis from the FUTURE 5 study including 996 patients with active PsA who were randomly assigned to receive secukinumab or placebo.

Disclosures: This study was funded by Novartis Pharma AG. Two authors declared being employees of or owning stocks/shares in Novartis, and several authors reported ties with various sources, including Novartis.

Source: Coates LC et al. Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: Results from the 2-year phase 3 FUTURE 5 study. RMD Open. 2023;9(2):e002939 (Apr 24). Doi: 10.1136/rmdopen-2022-002939

Key clinical point: Gout, a common inflammatory disease, is associated with a significantly increased risk for subsequent breast cancer (BC) diagnosis, particularly in young women aged ≤50 years.

Major finding: Gout was significantly associated with an increased risk for subsequent BC in the total population (hazard ratio [HR] 1.17; 95% CI 1.05-1.31), with the risk being more prominent among women who were ≤50 years of age (HR 1.58; 95% CI 1.10-2.27).

Study details: Findings are from a retrospective cohort study including 33,799 women with gout and 33,799 women without gout, of which 4.5% and 3.7% of women were diagnosed with BC during the 10 years of follow-up, respectively.

Disclosures: The lead author was supported by the Philipps-University of Marburg and the University Hospital of Giessen and Marburg. The authors declared no conflicts of interest.

Source: Gremke N et al. Association between gout and subsequent breast cancer: A retrospective cohort study including 67,598 primary care patients in Germany. Breast Cancer Res Treat. 2023;199:545-552 (Apr 18). Doi: 10.1007/s10549-023-06944-w

Key clinical point: Gout, a common inflammatory disease, is associated with a significantly increased risk for subsequent breast cancer (BC) diagnosis, particularly in young women aged ≤50 years.

Major finding: Gout was significantly associated with an increased risk for subsequent BC in the total population (hazard ratio [HR] 1.17; 95% CI 1.05-1.31), with the risk being more prominent among women who were ≤50 years of age (HR 1.58; 95% CI 1.10-2.27).

Study details: Findings are from a retrospective cohort study including 33,799 women with gout and 33,799 women without gout, of which 4.5% and 3.7% of women were diagnosed with BC during the 10 years of follow-up, respectively.

Disclosures: The lead author was supported by the Philipps-University of Marburg and the University Hospital of Giessen and Marburg. The authors declared no conflicts of interest.

Source: Gremke N et al. Association between gout and subsequent breast cancer: A retrospective cohort study including 67,598 primary care patients in Germany. Breast Cancer Res Treat. 2023;199:545-552 (Apr 18). Doi: 10.1007/s10549-023-06944-w

Key clinical point: Gout, a common inflammatory disease, is associated with a significantly increased risk for subsequent breast cancer (BC) diagnosis, particularly in young women aged ≤50 years.

Major finding: Gout was significantly associated with an increased risk for subsequent BC in the total population (hazard ratio [HR] 1.17; 95% CI 1.05-1.31), with the risk being more prominent among women who were ≤50 years of age (HR 1.58; 95% CI 1.10-2.27).

Study details: Findings are from a retrospective cohort study including 33,799 women with gout and 33,799 women without gout, of which 4.5% and 3.7% of women were diagnosed with BC during the 10 years of follow-up, respectively.

Disclosures: The lead author was supported by the Philipps-University of Marburg and the University Hospital of Giessen and Marburg. The authors declared no conflicts of interest.

Source: Gremke N et al. Association between gout and subsequent breast cancer: A retrospective cohort study including 67,598 primary care patients in Germany. Breast Cancer Res Treat. 2023;199:545-552 (Apr 18). Doi: 10.1007/s10549-023-06944-w

Key clinical point: Women with lymph-node positive early breast cancer (BC) had a high risk for cancer therapy-related cardiovascular toxicity (CTR-CVT), particularly if they were older or receiving anthracycline treatment.

Major finding: The cumulative incidence of CTR-CVT was 71.8%, with 54.0% of events occurring in patients who were 51-60 years old. Similarly, anthracycline treatment was associated with 51.0% of hypertension, 57.0% of coronary artery disease, 60.0% of heart failure, and 54.0% of atrial fibrillation events.

Study details: Findings are from a retrospective population-based cohort study including 433 women age <60 years with lymph node-positive early BC, of which 53.0%, 18.0%, and 29.0% of women received anthracycline, non-anthracycline-containing chemotherapy, and no chemotherapy, respectively.

Disclosures: This study was supported by the Stockholm County Council and other sources. Three authors declared receiving research funding, payments for traveling and accommodation, or lecture fees from various sources.

Source: Hubbert L et al. Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: A Swedish cohort study. Front Oncol. 2023;13:1095251 (Apr 19). Doi: 10.3389/fonc.2023.1095251

Key clinical point: Women with lymph-node positive early breast cancer (BC) had a high risk for cancer therapy-related cardiovascular toxicity (CTR-CVT), particularly if they were older or receiving anthracycline treatment.

Major finding: The cumulative incidence of CTR-CVT was 71.8%, with 54.0% of events occurring in patients who were 51-60 years old. Similarly, anthracycline treatment was associated with 51.0% of hypertension, 57.0% of coronary artery disease, 60.0% of heart failure, and 54.0% of atrial fibrillation events.

Study details: Findings are from a retrospective population-based cohort study including 433 women age <60 years with lymph node-positive early BC, of which 53.0%, 18.0%, and 29.0% of women received anthracycline, non-anthracycline-containing chemotherapy, and no chemotherapy, respectively.

Disclosures: This study was supported by the Stockholm County Council and other sources. Three authors declared receiving research funding, payments for traveling and accommodation, or lecture fees from various sources.

Source: Hubbert L et al. Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: A Swedish cohort study. Front Oncol. 2023;13:1095251 (Apr 19). Doi: 10.3389/fonc.2023.1095251

Key clinical point: Women with lymph-node positive early breast cancer (BC) had a high risk for cancer therapy-related cardiovascular toxicity (CTR-CVT), particularly if they were older or receiving anthracycline treatment.

Major finding: The cumulative incidence of CTR-CVT was 71.8%, with 54.0% of events occurring in patients who were 51-60 years old. Similarly, anthracycline treatment was associated with 51.0% of hypertension, 57.0% of coronary artery disease, 60.0% of heart failure, and 54.0% of atrial fibrillation events.

Study details: Findings are from a retrospective population-based cohort study including 433 women age <60 years with lymph node-positive early BC, of which 53.0%, 18.0%, and 29.0% of women received anthracycline, non-anthracycline-containing chemotherapy, and no chemotherapy, respectively.

Disclosures: This study was supported by the Stockholm County Council and other sources. Three authors declared receiving research funding, payments for traveling and accommodation, or lecture fees from various sources.

Source: Hubbert L et al. Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: A Swedish cohort study. Front Oncol. 2023;13:1095251 (Apr 19). Doi: 10.3389/fonc.2023.1095251

Key clinical point: Presence of depression before and after the diagnosis of breast cancer (BC) was associated with worsened survival outcomes in women with primary invasive BC.

Major finding: Compared with patients without depression, survival was worse among patients who had depression either before (hazard ratio [HR] 1.38; P = .007) or after (HR 1.48; P < .001) BC diagnosis but not among patients with persistent depression.

Study details: Findings are from an analysis of 6054 women with primary invasive BC from the Kentucky Cancer Registry, of which 3.7%, 6.0%, and 4.1% of patients had pre‐diagnosis depression only, post‐diagnosis depression only, and persistent depression, respectively.

Disclosures: This study was funded by US Centers for Disease Control and Prevention and other sources. Two authors declared receiving fees or grant funding from the funding agencies and other sources.

Source: Lei F et al. Influence of depression on breast cancer treatment and survival: A Kentucky population-based study. Cancer. 2023 (Apr 17). Doi: 10.1002/cncr.34676

Key clinical point: Presence of depression before and after the diagnosis of breast cancer (BC) was associated with worsened survival outcomes in women with primary invasive BC.

Major finding: Compared with patients without depression, survival was worse among patients who had depression either before (hazard ratio [HR] 1.38; P = .007) or after (HR 1.48; P < .001) BC diagnosis but not among patients with persistent depression.

Study details: Findings are from an analysis of 6054 women with primary invasive BC from the Kentucky Cancer Registry, of which 3.7%, 6.0%, and 4.1% of patients had pre‐diagnosis depression only, post‐diagnosis depression only, and persistent depression, respectively.

Disclosures: This study was funded by US Centers for Disease Control and Prevention and other sources. Two authors declared receiving fees or grant funding from the funding agencies and other sources.

Source: Lei F et al. Influence of depression on breast cancer treatment and survival: A Kentucky population-based study. Cancer. 2023 (Apr 17). Doi: 10.1002/cncr.34676

Key clinical point: Presence of depression before and after the diagnosis of breast cancer (BC) was associated with worsened survival outcomes in women with primary invasive BC.

Major finding: Compared with patients without depression, survival was worse among patients who had depression either before (hazard ratio [HR] 1.38; P = .007) or after (HR 1.48; P < .001) BC diagnosis but not among patients with persistent depression.

Study details: Findings are from an analysis of 6054 women with primary invasive BC from the Kentucky Cancer Registry, of which 3.7%, 6.0%, and 4.1% of patients had pre‐diagnosis depression only, post‐diagnosis depression only, and persistent depression, respectively.

Disclosures: This study was funded by US Centers for Disease Control and Prevention and other sources. Two authors declared receiving fees or grant funding from the funding agencies and other sources.

Source: Lei F et al. Influence of depression on breast cancer treatment and survival: A Kentucky population-based study. Cancer. 2023 (Apr 17). Doi: 10.1002/cncr.34676

Key clinical point: Germline pathogenic variants (PV) in genes other than BRCA1/2, such as ATM and PALB2, are associated with an increased risk for breast cancer (BC) in men.

Major finding: A higher proportion of males with vs without BC had PV in genes other than BRCA1/2 (4.8% vs 1.8%). Overall, PV in genes other than BRCA1/2 were associated with a >3-fold increased risk for BC (odds ratio [OR] 3.48; P < .0001), with the risk being even higher with PV in PALB2 (OR 7.28; P = .034) and ATM (OR 4.79; P = .035) genes.

Study details: Findings are from a retrospective, case-control study including 767 males with BC who were BRCA1/2-negative and 1349 male control individuals without a personal history of cancer.

Disclosures: This study was supported by Associazione Italiana Ricerca Cancro and other sources. The authors declared no conflicts of interest.

Source: Bucalo A et al. Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: An Italian case-control study. Eur J Cancer. 2023 (May 2). Doi: 10.1016/j.ejca.2023.04.022

Key clinical point: Germline pathogenic variants (PV) in genes other than BRCA1/2, such as ATM and PALB2, are associated with an increased risk for breast cancer (BC) in men.

Major finding: A higher proportion of males with vs without BC had PV in genes other than BRCA1/2 (4.8% vs 1.8%). Overall, PV in genes other than BRCA1/2 were associated with a >3-fold increased risk for BC (odds ratio [OR] 3.48; P < .0001), with the risk being even higher with PV in PALB2 (OR 7.28; P = .034) and ATM (OR 4.79; P = .035) genes.

Study details: Findings are from a retrospective, case-control study including 767 males with BC who were BRCA1/2-negative and 1349 male control individuals without a personal history of cancer.

Disclosures: This study was supported by Associazione Italiana Ricerca Cancro and other sources. The authors declared no conflicts of interest.

Source: Bucalo A et al. Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: An Italian case-control study. Eur J Cancer. 2023 (May 2). Doi: 10.1016/j.ejca.2023.04.022

Key clinical point: Germline pathogenic variants (PV) in genes other than BRCA1/2, such as ATM and PALB2, are associated with an increased risk for breast cancer (BC) in men.

Major finding: A higher proportion of males with vs without BC had PV in genes other than BRCA1/2 (4.8% vs 1.8%). Overall, PV in genes other than BRCA1/2 were associated with a >3-fold increased risk for BC (odds ratio [OR] 3.48; P < .0001), with the risk being even higher with PV in PALB2 (OR 7.28; P = .034) and ATM (OR 4.79; P = .035) genes.

Study details: Findings are from a retrospective, case-control study including 767 males with BC who were BRCA1/2-negative and 1349 male control individuals without a personal history of cancer.

Disclosures: This study was supported by Associazione Italiana Ricerca Cancro and other sources. The authors declared no conflicts of interest.

Source: Bucalo A et al. Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: An Italian case-control study. Eur J Cancer. 2023 (May 2). Doi: 10.1016/j.ejca.2023.04.022

Key clinical point: Chemotherapy plus endocrine therapy (CET) was more effective than endocrine therapy (ET) alone in improving overall survival (OS) outcomes in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) and a recurrence score (RS) of 20-25.

Major finding: Although OS was significantly inferior in patients with RS of >20 (P < .001-.019), CET vs ET improved OS in patients with RS of 20-25 regardless of age (age ≤50: hazard ratio [HR] 0.334; P = .002 and age >50: HR 0.521; P = .019).

Study details: This retrospective cohort study of real-world data from the US National Cancer Database included 28,427 women with stage I-III HR+/HER2− BC and 1-3 positive axillary lymph nodes, of which 26.3% and 73.7% of patients received CET and ET, respectively.

Disclosures: The lead author is supported by the Sociedade Beneficente Israelita Brasileira Albert Einstein. The authors declared no conflicts of interest.

Source: Stabellini N et al. Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: An NCDB analysis. Front Oncol. 2023;13:1115208 (Apr 24). Doi: 10.3389/fonc.2023.1115208

Key clinical point: Chemotherapy plus endocrine therapy (CET) was more effective than endocrine therapy (ET) alone in improving overall survival (OS) outcomes in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) and a recurrence score (RS) of 20-25.

Major finding: Although OS was significantly inferior in patients with RS of >20 (P < .001-.019), CET vs ET improved OS in patients with RS of 20-25 regardless of age (age ≤50: hazard ratio [HR] 0.334; P = .002 and age >50: HR 0.521; P = .019).

Study details: This retrospective cohort study of real-world data from the US National Cancer Database included 28,427 women with stage I-III HR+/HER2− BC and 1-3 positive axillary lymph nodes, of which 26.3% and 73.7% of patients received CET and ET, respectively.

Disclosures: The lead author is supported by the Sociedade Beneficente Israelita Brasileira Albert Einstein. The authors declared no conflicts of interest.

Source: Stabellini N et al. Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: An NCDB analysis. Front Oncol. 2023;13:1115208 (Apr 24). Doi: 10.3389/fonc.2023.1115208

Key clinical point: Chemotherapy plus endocrine therapy (CET) was more effective than endocrine therapy (ET) alone in improving overall survival (OS) outcomes in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) and a recurrence score (RS) of 20-25.

Major finding: Although OS was significantly inferior in patients with RS of >20 (P < .001-.019), CET vs ET improved OS in patients with RS of 20-25 regardless of age (age ≤50: hazard ratio [HR] 0.334; P = .002 and age >50: HR 0.521; P = .019).

Study details: This retrospective cohort study of real-world data from the US National Cancer Database included 28,427 women with stage I-III HR+/HER2− BC and 1-3 positive axillary lymph nodes, of which 26.3% and 73.7% of patients received CET and ET, respectively.

Disclosures: The lead author is supported by the Sociedade Beneficente Israelita Brasileira Albert Einstein. The authors declared no conflicts of interest.

Source: Stabellini N et al. Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: An NCDB analysis. Front Oncol. 2023;13:1115208 (Apr 24). Doi: 10.3389/fonc.2023.1115208